US EditionPublished • loading... • Updated
Crescel Reports Positive Randomized Controlled Trial Results for Biobotanical Skin Renewal Cream in Rosacea
In a 12-week randomized trial, Crescel Skin Renewal Cream reduced rosacea redness by 54% and inflammatory lesions by 74% with no significant side effects.
- On March 19–20, 2026, Crescel LLC announced in a Miami Beach release that its trial showed greater rosacea improvement with Crescel Skin Renewal Cream versus topical metronidazole 0.75% plus CeraVe moisturizer.
- The double-blind trial enrolled 60 adult subjects with mild to severe rosacea over a 12-week treatment period, randomized to Crescel or metronidazole 0.75% plus moisturizer twice daily with assessments at Weeks 4, 8 and 12.
- Clinical measures indicated Crescel cut inflammatory lesions by 74% at Week 8, maintained through Week 12, while redness dropped 54% at Week 12 versus 23% and 17% in the comparator.
- Tolerability data showed study participants reported no clinically relevant irritation, dryness, or skin barrier disruption, and the cream is endorsed by the National Rosacea Society Seal of Acceptance, the National Psoriasis Foundation Seal of Recognition, and available at www.crescel.com.
- Crescel's CEO said 'These findings support the potential for a new approach in managing rosacea,' and Dr. Roberta Shapiro praised 'Crescel's healing capabilities are exceptional.' Yonhap editor's note clarified the Crescel LLC press release was unedited.
Insights by Ground AI
36 Articles
36 Articles
Crescel reports positive trial results for rosacea cream
MIAMI BEACH, Fla., March 20, 2026 /PRNewswire/ -- Crescel LLC, an innovative science and technology company, today announced results from a double-blind, randomized, active comparator-controlled clinical trial evaluating its biobotanical Skin Renewal Cream compared to a commonly used standard of care—topical metronidazole (Metrocream®) combined with CeraVe® moisturizer—in individuals with rosacea, a chronic inflammatory skin condition. The study…
Coverage Details
Total News Sources36
Leaning Left4Leaning Right6Center11Last UpdatedBias Distribution52% Center
Bias Distribution
- 52% of the sources are Center
52% Center
L 19%
C 52%
R 29%
Factuality
To view factuality data please Upgrade to Premium
